Baclosign: Targeted Spasticity Relief with Precision Muscle Control
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.02 (0%) | 🛒 Add to cart |
| 90 | $0.68 | $73.53 $61.06 (17%) | 🛒 Add to cart |
| 120 | $0.62 | $98.04 $74.82 (24%) | 🛒 Add to cart |
| 180 | $0.59 | $147.06 $105.78 (28%) | 🛒 Add to cart |
| 270 | $0.57 | $220.59 $153.08 (31%) | 🛒 Add to cart |
| 360 | $0.53
Best per pill | $294.12 $191.78 (35%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.87 | $38.70 (0%) | 🛒 Add to cart |
| 20 | $3.40 | $77.40 $67.94 (12%) | 🛒 Add to cart |
| 30 | $2.72 | $116.10 $81.70 (30%) | 🛒 Add to cart |
| 60 | $2.59 | $232.20 $155.66 (33%) | 🛒 Add to cart |
| 90 | $2.45 | $348.30 $220.16 (37%) | 🛒 Add to cart |
| 120 | $2.31 | $464.40 $277.78 (40%) | 🛒 Add to cart |
| 180 | $2.14 | $696.60 $384.42 (45%) | 🛒 Add to cart |
| 270 | $2.00 | $1044.90 $540.94 (48%) | 🛒 Add to cart |
| 360 | $1.92
Best per pill | $1393.20 $690.58 (50%) | 🛒 Add to cart |
Baclosign (baclofen) is a centrally acting skeletal muscle relaxant specifically formulated for the management of spasticity resulting from multiple sclerosis, spinal cord injuries, and other neurological diseases. It functions as a gamma-aminobutyric acid (GABA) agonist, primarily acting at the spinal cord level to inhibit monosynaptic and polysynaptic reflex transmission. This targeted mechanism significantly reduces the frequency and/or severity of spasms and clonus while alleviating associated pain and improving range of motion. By modulating hyperactive reflex arcs, Baclosign facilitates enhanced functional capacity and daily comfort for patients with upper motor neuron syndromes, offering a well-established therapeutic option within a structured clinical management plan.
Features
- Active pharmaceutical ingredient: Baclofen USP
- Available in 10 mg and 20 mg oral tablet strengths
- White to off-white, round, biconvex, film-coated tablets
- Debossed with identifying markings for accurate dosing
- Formulated for consistent bioavailability and predictable pharmacokinetics
- Manufactured under cGMP (current Good Manufacturing Practices) standards
- Packaged in high-density polyethylene (HDPE) bottles with child-resistant caps
- Each batch undergoes rigorous analytical and microbiological testing
Benefits
- Reduces muscle spasticity and hypertonia, enabling improved voluntary movement
- Decreases the frequency and intensity of painful muscle spasms and clonus
- Enhances functional capacity for activities of daily living and rehabilitation efforts
- May improve bladder and bowel function by reducing sphincter dyssynergia
- Supports nursing care and positioning by easing rigidity and extensor spasms
- Provides a dose-titratable option for individualized patient management
Common use
Baclosign is indicated for the management of spasticity in patients with multiple sclerosis, spinal cord lesions (such as trauma, tumors, or transverse myelitis), and other spinal cord diseases. It is particularly effective in alleviating flexor spasms, concomitant pain, clonus, and muscular rigidity. Clinicians may also consider its off-label use in certain cases of cerebral palsy or spasticity of cerebral origin, though evidence is more limited for these indications. The goal of therapy is to achieve a reduction in disabling spasticity without inducing significant muscle weakness that could impair ambulation or function.
Dosage and direction
The dosage of Baclosign must be individualized for each patient. Therapy should be initiated at a low dose and gradually titrated upward to achieve an optimal response.
- Adults: Initial dose is 5 mg administered orally three times daily. The dose may be increased by 15 mg (e.g., one additional 5 mg tablet per dose) every 3 days until the desired effect is achieved. The average therapeutic range is 40–80 mg daily divided into 3–4 doses. Doses exceeding 80 mg daily are not recommended; the maximum daily dose should not exceed 100 mg.
- Children (age 12 and above): Use similar titration as in adults, though extreme caution and close monitoring are advised. Not typically recommended for children under 12.
- Administration: Tablets should be swallowed whole with a glass of water, with or without food. To minimize potential drowsiness or dizziness, doses may be taken with meals.
Dosage reduction should be gradual upon discontinuation to avoid withdrawal symptoms, including hallucinations and seizures.
Precautions
- Baclosign may cause drowsiness, dizziness, or blurred vision. Patients should be cautioned about operating machinery, driving, or engaging in hazardous activities until their response to the drug is known.
- Use with caution in patients with a history of peptic ulcer disease, cerebrovascular accident, or psychiatric disorders.
- Renal impairment significantly affects baclofen excretion. Dose reduction is necessary in patients with renal dysfunction (creatinine clearance <60 mL/min).
- Abrupt discontinuation may precipitate withdrawal syndrome, including visual hallucinations, seizures, and pruritus. Taper dose gradually over 1–2 weeks, or longer if high doses were used.
- Elderly patients may be more sensitive to the central nervous system effects and may require lower doses.
Contraindications
- Hypersensitivity to baclofen or any component of the formulation.
- Use in patients with psychotic disorders or uncontrolled epilepsy, unless potential benefits outweigh risks under strict supervision.
- Not recommended during pregnancy unless clearly needed; baclofen crosses the placenta and should be used only if the potential benefit justifies the potential risk to the fetus.
- Avoid use in breastfeeding mothers due to secretion into breast milk.
Possible side effect
Common adverse reactions (≥1%) include:
- Drowsiness
- Dizziness
- Weakness and fatigue
- Nausea
- Constipation
- Headache
- Insomnia
- Hypotension
Less common but serious side effects may include:
- Hallucinations or confusion
- seizures
- Severe hypotension or bradycardia
- Respiratory depression
- Rash or allergic reactions
- Urinary retention
- Exacerbation of spasticity (paradoxical effect)
Drug interaction
- CNS Depressants (e.g., alcohol, benzodiazepines, opioids, sedating antihistamines): Enhanced sedative effects; concurrent use requires caution.
- Antihypertensives: May potentiate hypotensive effects.
- MAO Inhibitors: May increase CNS depression or hypotension.
- Levodopa: Reports of worsened psychiatric symptoms or hallucinations.
- Tricyclic Antidepressants: May increase muscle relaxant effects.
Always review the patient’s full medication list before initiating Baclosign.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one.
Overdose
Symptoms of overdose may include:
- vomiting
- muscular hypotonia
- drowsiness progressing to coma
- respiratory depression
- seizures
- hypothermia
Management is primarily supportive. Ensure airway patency, monitor vital signs, and consider gastric lavage if ingestion was recent. There is no specific antidote. Hemodialysis may be beneficial in removing baclofen, especially in patients with renal impairment.
Storage
Store at controlled room temperature (20°–25°C or 68°–77°F), in a dry place protected from light and moisture. Keep the bottle tightly closed and out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and before starting or changing any treatment regimen. The prescribing physician should be familiar with the full prescribing information and the individual patient’s medical history.
Reviews
“Baclosign has been a cornerstone in my MS patients’ spasticity management. The predictable titration and clear response make it a reliable choice. Most patients report significant improvement in comfort and mobility with careful dosing.” — Neurologist, 14 years of experience
“As a rehab specialist, I appreciate the functional gains my spinal cord injury patients achieve with Baclosign. It reduces painful spasms and improves seating tolerance. We always emphasize gradual dose adjustment.” — Physical Medicine and Rehabilitation Physician
“Effective, but requires monitoring for sedation, especially in the elderly. When dosed appropriately, it markedly improves quality of life.” — General Practitioner